{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:59:31Z","timestamp":1790888371322,"version":"4.1.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T00:00:00Z","timestamp":1597708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/P006264\/1"],"award-info":[{"award-number":["MR\/P006264\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["104033"],"award-info":[{"award-number":["104033"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"name":"EUROHEADPAIN","award":["602633"],"award-info":[{"award-number":["602633"]}]},{"DOI":"10.13039\/501100000283","name":"Migraine Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000283","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["DA40688"],"award-info":[{"award-number":["DA40688"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Development and Promotion of Science and Technology Talents Project"},{"name":"DPST"},{"name":"Royal Thai Government"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Medication overuse headache is estimated to affect 2% of the population, and is ranked in the top 20 most disabling disorders due to its high level of disability. Several therapies used in the treatment of acute migraine are thought to be associated with medication overuse headache, including opioids and triptans. With limited treatment options, it is critical to determine the risk profile of novel therapies prior to their widespread use. The current study explores the potential medication overuse risk of two novel therapeutic drug classes, namely the ditans: 5-HT1F receptor agonists, and the gepants: calcitonin gene-related peptide receptor antagonists, in a preclinical model of medication overuse. Persistent exposure of mice to the 5-HT1F agonist LY344864, but not olcegepant produced a significant reduction in hind paw and orofacial mechanical withdrawal thresholds as a surrogate readout of allodynia. In agreement, only LY344864 induced neuroplastic changes in trigeminal sensory afferents, increasing calcitonin gene-related peptide expression and basal trigeminal nociception. Our data highlight a differential medication overuse headache risk profile for the ditan and gepant classes of drugs that has important implications for their clinical use and patient education to help reduce the burden of medication overuse headache.<\/jats:p>","DOI":"10.1093\/brain\/awaa211","type":"journal-article","created":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T19:16:59Z","timestamp":1592939819000},"page":"2681-2688","source":"Crossref","is-referenced-by-count":63,"title":["Differential medication overuse risk of novel anti-migraine therapeutics"],"prefix":"10.1093","volume":"143","author":[{"given":"Chonlawan","family":"Saengjaroentham","sequence":"first","affiliation":[{"name":"Headache Group, Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King\u2019s College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0182-0962","authenticated-orcid":false,"given":"Lauren C","family":"Strother","sequence":"additional","affiliation":[{"name":"Headache Group, Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King\u2019s College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac","family":"Dripps","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Illinois at Chicago, Chicago, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Rayhan","family":"Sultan Jabir","sequence":"additional","affiliation":[{"name":"Headache Group, Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King\u2019s College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9691-2976","authenticated-orcid":false,"given":"Amynah","family":"Pradhan","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Illinois at Chicago, Chicago, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3260-5904","authenticated-orcid":false,"given":"Peter J","family":"Goadsby","sequence":"additional","affiliation":[{"name":"Headache Group, Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King\u2019s College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3345-4853","authenticated-orcid":false,"given":"Philip R","family":"Holland","sequence":"additional","affiliation":[{"name":"Headache Group, Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King\u2019s College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,8,18]]},"reference":[{"key":"2020111212331274900_awaa211-B1","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1046\/j.1526-4610.2003.03041.x","article-title":"Does chronic daily headache arise de novo in association with regular use of analgesics?","volume":"43","author":"Bahra","year":"2003","journal-title":"Headache"},{"key":"2020111212331274900_awaa211-B2","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1111\/j.1526-4610.2008.01217.x","article-title":"Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study","volume":"48","author":"Bigal","year":"2008","journal-title":"Headache"},{"key":"2020111212331274900_awaa211-B3","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1038\/s41467-019-12197-3","article-title":"Maladaptive activation of Nav1.9 channels by nitric oxide causes triptan-induced medication overuse headache","volume":"10","author":"Bonnet","year":"2019","journal-title":"Nat Commun"},{"key":"2020111212331274900_awaa211-B4","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1177\/0333102417728244","article-title":"A systematic review and critical appraisal of gene polymorphism association studies in medication-overuse headache","volume":"38","author":"Cargnin","year":"2018","journal-title":"Cephalalgia"},{"key":"2020111212331274900_awaa211-B5","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0165-0270(94)90144-9","article-title":"Quantitative assessment of tactile allodynia in the rat paw","volume":"53","author":"Chaplan","year":"1994","journal-title":"J Neurosci Methods"},{"key":"2020111212331274900_awaa211-B6","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/ana.21897","article-title":"Triptan-induced latent sensitization: a possible basis for medication overuse headache","volume":"67","author":"De Felice","year":"2010","journal-title":"Ann Neurol"},{"key":"2020111212331274900_awaa211-B7","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1523\/JNEUROSCI.23-03-00807.2003","article-title":"Stimulation of the calcitonin gene-related peptide enhancer by mitogen-activated protein kinases and repression by an antimigraine drug in trigeminal ganglia neurons","volume":"23","author":"Durham","year":"2003","journal-title":"J Neurosci"},{"key":"2020111212331274900_awaa211-B8","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1002\/ejp.1383","article-title":"Complete withdrawal is the most feasible treatment for medication-overuse headache: a randomized controlled open-label trial","volume":"23","author":"Engelstoft","year":"2019","journal-title":"Eur J Pain"},{"key":"2020111212331274900_awaa211-B9","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/S1474-4422(18)30322-3","article-title":"Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"17","year":"2018","journal-title":"Lancet Neurol"},{"key":"2020111212331274900_awaa211-B10","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"392","year":"2018","journal-title":"Lancet"},{"key":"2020111212331274900_awaa211-B11","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0140-6736(15)60692-4","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013","volume":"386","year":"2015","journal-title":"Lancet"},{"key":"2020111212331274900_awaa211-B12","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0306-4522(03)00570-0","article-title":"Evidence for serotonin (5-HT)1B, 5-HT1D and 5-HT1F receptor inhibitory effects on trigeminal neurons with craniovascular input","volume":"122","author":"Goadsby","year":"2003","journal-title":"Neuroscience"},{"key":"2020111212331274900_awaa211-B13","first-page":"92","article-title":"Orally administered atogepant was efficacious, safe, and tolerable for the prevention of migraine: results from a phase 2b\/3 Study","author":"Goadsby","year":"2019","journal-title":"Neurology"},{"key":"2020111212331274900_awaa211-B14","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s10194-019-1043-7","article-title":"Animal models of migraine and experimental techniques used to examine trigeminal sensory processing","volume":"20","author":"Harriott","year":"2019","journal-title":"J Headache Pain"},{"key":"2020111212331274900_awaa211-B15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/0333102417738202","article-title":"The International Classification of Headache Disorders, 3rd edition","volume":"38","year":"2018","journal-title":"Cephalalgia"},{"key":"2020111212331274900_awaa211-B16","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1097\/j.pain.0000000000001801","article-title":"Lasmiditan Inhibits calcitonin gene-related peptide release in the rodent trigeminovascular system","volume":"161","author":"Labastida-Ramirez","year":"2020","journal-title":"Pain"},{"key":"2020111212331274900_awaa211-B17","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/j.1468-1331.2011.03612.x","article-title":"The cost of headache disorders in Europe: the Eurolight project","volume":"19","author":"Linde","year":"2012","journal-title":"Eur J Neurol"},{"key":"2020111212331274900_awaa211-B18","doi-asserted-by":"crossref","first-page":"e2224","DOI":"10.1212\/WNL.0000000000008589","article-title":"Migraine progression in subgroups of migraine based on comorbidities: results of the CaMEO Study","volume":"93","author":"Lipton","year":"2019","journal-title":"Neurology"},{"key":"2020111212331274900_awaa211-B19","first-page":"72","article-title":"The role of Nav1.9 channel in the development of neuropathic orofacial pain associated with trigeminal neuralgia","volume":"11","author":"Luiz","year":"2015","journal-title":"Mol Pain"},{"key":"2020111212331274900_awaa211-B20","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.neuropharm.2018.12.017","article-title":"Delta opioid receptor agonists are effective for multiple types of headache disorders","volume":"148","author":"Moye","year":"2019","journal-title":"Neuropharmacology"},{"key":"2020111212331274900_awaa211-B21","first-page":"S58.007","article-title":"Efficacy of Ubrogepant in a Preclinical Model of Medication Overuse Headache","volume":"94 (15 Suppl","author":"Navratilova","year":"2020","journal-title":"Neurology"},{"key":"2020111212331274900_awaa211-B22","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s10194-019-1044-6","article-title":"Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials","volume":"20","author":"Shapiro","year":"2019","journal-title":"J Headache Pain"},{"key":"2020111212331274900_awaa211-B23","doi-asserted-by":"crossref","first-page":"e2309","DOI":"10.1212\/WNL.0000000000007497","article-title":"Erenumab in chronic migraine with medication overuse: subgroup analysis of a randomized trial","volume":"92","author":"Tepper","year":"2019","journal-title":"Neurology"},{"key":"2020111212331274900_awaa211-B24","doi-asserted-by":"crossref","first-page":"9547056","DOI":"10.1155\/2017\/9547056","article-title":"Effects of NSAIDs on the release of calcitonin gene-related peptide and prostaglandin E2 from rat trigeminal ganglia","volume":"2017","author":"Vellani","year":"2017","journal-title":"Mediators Inflamm"},{"key":"2020111212331274900_awaa211-B25","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1177\/0333102413512033","article-title":"Definitions of medication-overuse headache in population-based studies and their implications on prevalence estimates: a systematic review","volume":"34","author":"Westergaard","year":"2014","journal-title":"Cephalalgia"}],"container-title":["Brain"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/brain\/article-pdf\/143\/9\/2681\/34279776\/awaa211.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/brain\/article-pdf\/143\/9\/2681\/34279776\/awaa211.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T07:40:00Z","timestamp":1723102800000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/brain\/article\/143\/9\/2681\/5894039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,18]]},"references-count":25,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,8,18]]},"published-print":{"date-parts":[[2020,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/brain\/awaa211","relation":{},"ISSN":["0006-8950","1460-2156"],"issn-type":[{"value":"0006-8950","type":"print"},{"value":"1460-2156","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,9]]},"published":{"date-parts":[[2020,8,18]]}}}